Drug Overview

Seviteronel is an advanced, experimental medication designed to treat hormone-driven cancers, such as certain types of breast and prostate cancer. It belongs to a modern class of drugs that stop the body from producing the hormones that tumors use to grow. Unlike older treatments that may only block one pathway, this medication is designed to be more precise and thorough in its approach.

As a Targeted Therapy and a Smart Drug, seviteronel is currently being studied in clinical trials to determine its safety and effectiveness. It is not yet available at local pharmacies and can only be accessed by patients who choose to join approved medical research studies.

• Generic name: Seviteronel (also known as VT-464)
• US Brand names: None (Investigational drug)
• Drug Class: CYP17 lyase inhibitor, Androgen receptor antagonist
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Seviteronel works by cutting off the fuel supply to cancer cells. Many breast and prostate cancers are “hormone-sensitive,” meaning they need hormones like testosterone or estrogen to multiply.

At the molecular level, the drug targets a specific enzyme called CYP17. This enzyme is like a factory worker that helps create androgen and estrogen hormones in the adrenal glands, the gonads, and even inside the tumor itself. While some older drugs block the entire CYP17 factory, seviteronel is more selective. It specifically blocks the “lyase” activity of the enzyme. This is a “Smart Drug” characteristic because it reduces the production of growth-driving hormones while allowing the body to keep making other essential life-sustaining hormones, like cortisol.

Furthermore, seviteronel has a second job. It acts as an androgen receptor antagonist. This means it also sits on the “docking stations” (receptors) on the surface of the cancer cell. By occupying these stations, it prevents any remaining hormones in the blood from connecting to the cell and sending growth signals. This dual action—stopping the hormone production and blocking the hormone reception—makes it a very powerful tool in research.

FDA Approved Clinical Indications

Because seviteronel is still in the testing phase, it does not have official FDA-approved uses for the general public. It is currently being evaluated in clinical trials for:

Oncological uses

• Investigational treatment for metastatic castration-resistant prostate cancer (mCRPC).
• Investigational treatment for Triple-Negative Breast Cancer (TNBC) that expresses the androgen receptor.
• Investigational treatment for advanced Estrogen Receptor-positive (ER+) breast cancer that has become resistant to other hormone therapies.

Non-oncological

• None at this time.

Dosage and Administration Protocols

The following table reflects the standard doses used in recent Phase 1 and Phase 2 clinical trials. Because it is experimental, the exact dose for a patient is determined by the specific research study protocol.

Dose Adjustments:

In clinical trials, if a patient develops severe side effects, doctors may reduce the dose to 300 milligrams daily. Because the liver processes this medication, patients with significant hepatic (liver) insufficiency are usually monitored very closely or excluded from trials. There is currently no standard guidance for dose changes in renal (kidney) insufficiency, but kidney function is checked regularly during treatment.

Clinical Efficacy and Research Results

Recent clinical research data from the 2020 to 2025 period have focused on how seviteronel performs in patients whose cancer has already failed other treatments.

In trials for prostate cancer (such as the INO-vAtE study), numerical data showed that seviteronel was able to lower Prostate-Specific Antigen (PSA) levels in a portion of patients who had already failed drugs like abiraterone or enzalutamide. In breast cancer trials, specifically for patients with androgen receptor-positive “Triple-Negative” tumors, the drug showed a clinical benefit rate of approximately 25 percent to 30 percent at the 16-week mark. This means that for nearly a third of these difficult-to-treat patients, the cancer stopped growing or shrank for at least four months. Researchers are currently using these results to determine which genetic markers make a patient most likely to respond to this therapy.

Safety Profile and Side Effects

As with all hormone-altering therapies, seviteronel has a specific safety profile that patients must understand.

Black Box Warning:

Because seviteronel is an investigational medication and not yet on the open market, it does not carry an official FDA Black Box Warning.

Common side effects

These side effects occurred in more than 10 percent of trial participants:

• Feeling very tired or weak (fatigue)
• Nausea and loss of appetite
• Hot flashes (similar to menopause symptoms)
• Dizziness or lightheadedness
• Temporary changes in taste

Serious adverse events:

• Significant decreases in white blood cell or platelet counts.
• Elevations in liver enzymes (indicating liver stress).
• Potential for heart rhythm changes, specifically a “prolonged QT interval” on a heart trace.
• Allergic reactions including skin rashes.

Management strategies:

Most mild side effects, like nausea, can be managed with standard over-the-counter stomach medications. If a patient experiences significant fatigue, doctors may suggest taking the medication at night. To ensure heart safety, patients in clinical trials are required to have regular electrocardiograms (EKGs). If liver enzymes rise too high, the drug is paused until the levels return to normal.

Research Areas

Seviteronel is currently being studied for its potential in combination with modern Immunotherapy. Researchers believe that by reducing the hormone levels that suppress the immune system, seviteronel might help the body’s natural T-cells find and destroy hidden cancer cells. Additionally, there is interest in how this drug affects “cancer stem cells.” These are the stubborn cells that often survive standard chemotherapy and cause the cancer to return years later. By cutting off the androgen signals to these stem cells, scientists hope to achieve longer-lasting remissions.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• A blood test to check baseline liver and kidney function.
• A baseline electrocardiogram (EKG) to check heart rhythm.
• For breast cancer patients, a biopsy to confirm the presence of the Androgen Receptor (AR+).
• A complete blood count (CBC) to check white and red blood cell levels.

Precautions during treatment:

Patients should be aware that this medication can interact with other drugs that affect heart rhythm. It is important to avoid new medications without checking with the oncology team. Because the drug can cause dizziness, patients should use caution when driving or operating heavy machinery until they know how the drug affects them.

Do’s and Don’ts list:

• Do take the tablet at the same time every day to keep the medicine levels steady in your blood.
• Do report any sudden fainting spells or heart palpitations to your doctor immediately.
• Do stay hydrated to help manage nausea and fatigue.
• Don’t stop taking the medication suddenly without talking to your research team.
• Don’t take any herbal supplements, especially St. John’s Wort, as they can interfere with how the liver processes the drug.
• Don’t ignore signs of yellowing skin or eyes, as this could indicate a liver problem.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Seviteronel is an investigational medication and is not approved by the Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.